Does TAFASITAMAB Cause Second primary malignancy? 11 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 11 reports of Second primary malignancy have been filed in association with TAFASITAMAB (MONJUVI). This represents 0.8% of all adverse event reports for TAFASITAMAB.
11
Reports of Second primary malignancy with TAFASITAMAB
0.8%
of all TAFASITAMAB reports
0
Deaths
2
Hospitalizations
How Dangerous Is Second primary malignancy From TAFASITAMAB?
Of the 11 reports, 2 (18.2%) required hospitalization, and 1 (9.1%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
Yes, Second primary malignancy is listed as a known adverse reaction in the official FDA drug label for TAFASITAMAB.
What Other Side Effects Does TAFASITAMAB Cause?
Disease progression (470)
Diffuse large b-cell lymphoma (346)
Off label use (203)
Death (146)
Neutropenia (99)
Covid-19 (96)
General physical health deterioration (75)
Pneumonia (66)
Febrile neutropenia (64)
Drug ineffective (62)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which TAFASITAMAB Alternatives Have Lower Second primary malignancy Risk?
TAFASITAMAB vs TAFASITAMAB-CXIX
TAFASITAMAB vs TAFINLAR
TAFASITAMAB vs TAFLUPROST
TAFASITAMAB vs TAGRAXOFUSP-ERZS
TAFASITAMAB vs TAHOR